Centessa Pharmaceuticals has initiated a Phase II trial of ORX750, an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia. ORX750 was designed using Nxera Pharma technology to directly… Read More
Novo Holdings has co-led a $181.4 million Series D financing in Alentis Therapeutics, a clinical-stage biotechnology company, headquartered in Basel, Switzerland, which is developing a pipeline of Claudin-1 (CLDN1) targeted medicines. This financing will enable Alentis to begin Phase I/II trials for two first-in-class ADCs: ALE.P02, which… Read More
NervGen Pharma’s lead drug candidate, NVG-291, is being evaluated in an ongoing Phase Ib/IIa clinical trial in partnership with Shirley Ryan AbilityLab for patients with spinal cord injury (SCI). Unlike traditional approaches that manage symptoms, NVG-291 empowers the nervous system to repair itself. DDW’s Megan Thomas speaks with President and… Read More
Infinitopes presented three posters on its cancer vaccine discovery and development strategy, including one that has been recognised as a ‘top 100’ poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10 November. A spinout from Oxford University, supported by Cancer Research UK (CRUK),… Read More
EnteroBiotix has announced positive results from its Phase Ib IMPuLCE study evaluating EBX-102 in patients with liver cirrhosis. EnteroBiotix’s first-in-human study of EBX-102 was a randomised, double-blind, placebo-controlled Phase Ib study of adult participants with stable liver cirrhosis. It was designed to evaluate the safety, tolerability, and… Read More
Storm Therapeutics has presented promising data from its Phase I clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the Society of Immunotherapy for Cancer (SITC) 39)th Annual Meeting, held in Houston, US, from 6-10 November 2024. The Phase I clinical study… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE,… Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected… Read More
DDW’s Multimedia Editor Megan Thomas attended the Society for Neuroscience (SfN)’s Neuroscience 2024 in October 2024 in Chicago, US. Having attended a range of presentations, explored the exhibition and engaged with industry attendees, she reflects on the event. News updates Whilst Neuroscience 2024 took place,… Read More
In September 2024, DDW’s Megan Thomas attended the opening of the Genolier Campus, a campus that includes the Clinique de Genolier, the Genolier Innovation Hub, the Clinique Nescens and the Swiss Visio Network. The campus is dedicated to medical research, innovation and the training of healthcare professionals. … Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week that saw a second monoclonal antibody rejected by UK regulator NICE,… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Owen Smith, Partner at… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Owen Smith, Partner at… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Owen Smith, Partner at… Read More
This is the latest episode of the free DDW narrated podcast, titled “How to streamline regulatory approval”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Quicker time to regulatory submission through improved data management and The… Read More
